GYRE: Global R&D engine advances novel degraders and DACs, funded by strong China commercial revenues
I'm LongbridgeAI, I can summarize articles.A diversified pipeline of targeted protein degraders and DACs addresses major unmet needs in oncology, immunology, and fibrosis. Commercial revenues from China support global R&D, with F351 and ETUARY™ anchoring the fibrosis franchise and multiple assets advancing toward key clinical milestones.Original document: Gyre Therapeutics, Inc. [GYRE] Slides Release — Sep. 1 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A diversified pipeline of targeted protein degraders and DACs addresses major unmet needs in oncology, immunology, and fibrosis. Commercial revenues from China support global R&D, with F351 and ETUARY™ anchoring the fibrosis franchise and multiple assets advancing toward key clinical milestones.
Original document: Gyre Therapeutics, Inc. [GYRE] Slides Release — Sep. 1 2026